Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial

C. Müller-Tidow, MD, Gesine Bug, MD, Richard Schlenk, MD, Michael Lübbert, MD, PhD, Alwin Krämer, MD, Juergen Krauter, MD, David Nachbaur, MD, Peter Valent, MD, Tillmann Taube, MD, Gerd Munzert, MD, Kang-Hun Lee, MD, Hartmut Dohner, MD

Blood (2008) 112 (11): 2973.

https://doi.org/10.1182/blood.V112.11.2973.2973

Published: 2008

Journal Articles

Genomic Changes Associated with Leukemic Transformation of Myeloproliferative Disorders.

Nils Heinrich Thoennissen, Norihiko Kawamata, MD, Terra L Lasho, MT(ASCP), Tamara Weiss, Daniel Nowak, Motohiro Kato, Junko Takita, MD, Masashi Sanada, Torsten Haferlach, MD, Ruben A. Mesa, MD, FACP, Ayalew Tefferi, MD, C. Müller-Tidow, MD, Seishi Ogawa, MD, PhD, Phillip H Koeffler

Blood (2008) 112 (11): 3371.

https://doi.org/10.1182/blood.V112.11.3371.3371

Published: 2008

Journal Articles

Expression of Circadian Core Clock Gene Per2 Is Markedly Down-Regulated in Diffuse Large B-Cell Lymphoma

Nils Heinrich Thoennissen, Qi Cao, BaoNgan Doan, Sam Abbassi, Daniel Nowak, C. Müller-Tidow, MD, Jonathan Said, MD, Sigal Gary, H. Phillip Koeffler, MD

Blood (2008) 112 (11): 4470.

https://doi.org/10.1182/blood.V112.11.4470.4470

Published: 2008

Journal Articles

A Multicentre Phase II Study of the Aminopeptidase Inhibitor, CHR- 2797, in the Treatment of Elderly and/or Previously Treated patients with Acute Myeloid Leukemia.

B. Lowenberg, MD, F. Davies, MD, C. Müller-Tidow, MD, Ulrich Dührsen, A. Burnett, MD, FRCP, P. Zachée, MD, PhD, D. Dierickx, MD, C. Jenkins, MD, P. Sonneveld, MD, M. Jongen-Lavrencic, MD, S. Zweegman, MD, G. Morgan, MD, U. Krug, MD, A. Richardson, PhD, L. Hooftman, MD, G. Ossenkoppele, MD, PhD

Blood (2008) 112 (11): 961.

https://doi.org/10.1182/blood.V112.11.961.961

Published: 2008

Journal Articles

Frequent in Vivo redundancy of C/EBPβ and C/EBPε during Myeloid Development

Nils Heinrich Thoennissen, Tadayuki Akagi, Sam Abbassi, Daniel Nowak, Ann George, Gay M. Crooks, MD, C. Müller-Tidow, MD, Adrian F Gombart, Phillip H Koeffler

Blood (2008) 112 (11): 2440.

https://doi.org/10.1182/blood.V112.11.2440.2440

Published: 2008

Journal Articles

ChIP-on-Chip Analysis Using Dominant Negative Form of PAX5 Fusion Gene Revealed Genes Associated with Tumorigenesis Were Directly Regulated by PAX5 in a Human B Cell Line, NALM6

Norihiko Kawamata, MD, Fabienne Isken, Stefanie Goellner, C. Müller-Tidow, MD, H. Phillip Koeffler, MD

Blood (2008) 112 (11): 3585.

https://doi.org/10.1182/blood.V112.11.3585.3585

Published: 2008

NARROW

Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial

Genomic Changes Associated with Leukemic Transformation of Myeloproliferative Disorders.

Expression of Circadian Core Clock Gene Per2 Is Markedly Down-Regulated in Diffuse Large B-Cell Lymphoma

A Multicentre Phase II Study of the Aminopeptidase Inhibitor, CHR- 2797, in the Treatment of Elderly and/or Previously Treated patients with Acute Myeloid Leukemia.

Frequent in Vivo redundancy of C/EBPβ and C/EBPε during Myeloid Development

ChIP-on-Chip Analysis Using Dominant Negative Form of PAX5 Fusion Gene Revealed Genes Associated with Tumorigenesis Were Directly Regulated by PAX5 in a Human B Cell Line, NALM6

Email alerts

ASH Publications

American Society of Hematology

Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial

Genomic Changes Associated with Leukemic Transformation of Myeloproliferative Disorders.

Expression of Circadian Core Clock Gene Per2 Is Markedly Down-Regulated in Diffuse Large B-Cell Lymphoma

A Multicentre Phase II Study of the Aminopeptidase Inhibitor, CHR- 2797, in the Treatment of Elderly and/or Previously Treated patients with Acute Myeloid Leukemia.

Frequent in Vivo redundancy of C/EBPβ and C/EBPε during Myeloid Development

ChIP-on-Chip Analysis Using Dominant Negative Form of PAX5 Fusion Gene Revealed Genes Associated with Tumorigenesis Were Directly Regulated by PAX5 in a Human B Cell Line, NALM6

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only